Drug Trial Radar · NCT06872892
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,755
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Jun 15, 2027
Study completion Dec 20, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Bronchiectasis
Interventions
BI 1291583Drug
BI 1291583
Placebo matching BI 1291583Drug
Placebo matching BI 1291583
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualised rate of adjudicated pulmonary exacerbations (number of events per person year) up to Week 76Time frame: up to 76 weeks
Locations
474 sites in 46 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of Arizona
Tucson, Arizona · Active not recruiting
Newport Native MD, Inc
Newport Beach, California · Active not recruiting
Paradigm Clinical Research - Redding
Redding, California · Active not recruiting
University of California Davis
Sacramento, California · Active not recruiting
University of California San Francisco
San Francisco, California · Active not recruiting
Ventura County Medical Center
Ventura, California · Completed
National Jewish Health
Denver, Colorado · Active not recruiting
Yale University School of Medicine
North Haven, Connecticut · Active not recruiting
Georgetown University
Washington D.C., District of Columbia · Active not recruiting
Meris Clinical Research-Brandon-69466
Brandon, Florida · Active not recruiting
St. Francis Medical Institute
Clearwater, Florida · Completed
North Florida/South Georgia Veterans Health System
Gainesville, Florida · Completed
University of Florida College of Medicine
Jacksonville, Florida · Completed
Mayo Clinic - Florida
Jacksonville, Florida · Active not recruiting
University of Miami
Miami, Florida · Active not recruiting
Essence MD Research
Naples, Florida · Active not recruiting
Vantage Clinical Trials - Tampa
Tampa, Florida · Active not recruiting
Cleveland Clinic Florida
Weston, Florida · Active not recruiting
Emory University
Atlanta, Georgia · Completed
Augusta University
Augusta, Georgia · Active not recruiting
Indiana University
Indianapolis, Indiana · Completed
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Completed
University of Kansas Medical Center
Kansas City, Kansas · Active not recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Completed
University of Maryland St. Joseph Medical Group Pulmonary Care and Sleep Medicine
Towson, Maryland · Completed
Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
UMASS Memorial Medical Center
Worcester, Massachusetts · Active not recruiting
University of Michigan
Ann Arbor, Michigan · Active not recruiting
Mayo Clinic, Rochester
Rochester, Minnesota · Active not recruiting
HealthPartners Specialty Center 401 Building
Saint Paul, Minnesota · Active not recruiting
University Of Mississippi Medical Center
Jackson, Mississippi · Active not recruiting
The Lung Research Center, LLC
Chesterfield, Missouri · Completed
Washington University School of Medicine
St Louis, Missouri · Active not recruiting
Washington University School of Medicine
St Louis, Missouri · Completed
University of Nebraska Medical Center
Omaha, Nebraska · Active not recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire · Completed
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey · Active not recruiting
New York Medical College - Hawthorne
Hawthorne, New York · Active not recruiting
Northwell Health
New Hyde Park, New York · Active not recruiting
Showing 40 of 474 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.